The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...
The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...
Hosted on MSN1mon
Atropine offers hope for mysterious Rajouri illnessSRINAGAR: In a major breakthrough, the doctors at GMC Rajouri have administered atropine to treat 11 patients who fell ill from a mysterious illness in Badhal village of J&K’s Rajouri.
Treated with atropine, the patients showed unexpected recovery, and doctors are awaiting details on the toxin to ensure long-term protection. No new cases emerged in the past four days.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results